Indications and Mechanism of ActionCrizotinib is indicated for patients with ALK‑positive locally advanced or metastatic non‑small cell lung cancer (N···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 216
FDA Approval AnnouncementYesterday, the U.S. Food and Drug Administration (FDA) approved an extended duration of use for Prevymis (letermovir), from 1···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 265
FDA Approval AnnouncementAccording to a press release from Merck & Co., Inc. dated June 6, the U.S. Food and Drug Administration (FDA) has approve···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 228
Drug Interactions of Letermovir TabletsConcomitant Medications That Are Strictly ContraindicatedConcomitant use with the following drugs is strictly p···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 222
Mechanism of Action and Therapeutic EffectsLetermovir tablets are an antiviral medication with the active ingredient letermovir, specifically indicate···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 226
Entrectinib is a targeted therapy for NTRK gene fusion-positive solid tumors and ROS1-positive non-small cell lung cancer. Its price varies depending ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 206
Crizotinib (Xalkori) is an oral kinase inhibitor that may be used to treat:1.Adults with non-small cell lung cancer which has spread to other parts of···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 243
Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F).【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 234
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may incre···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 250
If a dose of crizotinib is missed, it should be taken as soon as you remember. If it is close to the time of the next dose (within 6 hours), the misse···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 225
Clinical Background of ALK-Positive NSCLCLung cancer is one of the leading causes of cancer-related death worldwide, accounting for the highest number···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 199
FDA Approval AnnouncementMarch 11, 2016 -- The U.S. Food and Drug Administration (FDA) approved Xalkori (crizotinib) for the treatment of patients wit···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 204
FDA Approval AnnouncementNEW YORK--(BUSINESS WIRE) January 14, 2021 -- Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FD···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 202
FDA Approval AnnouncementOn July 14, 2022, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediat···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 264
Follow your doctor's instructions about any restrictions on food, beverages, or activity.【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 260
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos